← All Vaccines

💨

RSV Vaccines

21/27 total

Three Phase 3 trials evaluated RSV vaccines approved in 2023 for adults 60+.

Arexvy (GSK) — AReSVi-006 Phase 3

Papi et al., NEJM 2023

7/9
Sample size N = 24,966
Follow-up 6 months
Reported efficacy 82.6% against RSV lower respiratory tract disease
Funding GlaxoSmithKline (manufacturer)
7/9 criteria met (78%)
Criterion Met
Control Group ✅
Randomized ✅
Double-Blind ✅
Placebo-Controlled ✅
Large Sample (1,000+) ✅
Long Follow-up (1yr+) ❌
Independent Funding ❌
Peer-Reviewed ✅
Results Reproduced ✅

All three RSV trials share the same methodological gap: short 6-month follow-up windows insufficient to assess durability of protection.

Abrysvo (Pfizer) — RENOIR Phase 3

Walsh et al., NEJM 2023

7/9
Sample size N = 34,284
Follow-up 6 months
Reported efficacy 66.7% against RSV lower respiratory tract disease
Funding Pfizer (manufacturer)
7/9 criteria met (78%)
Criterion Met
Control Group ✅
Randomized ✅
Double-Blind ✅
Placebo-Controlled ✅
Large Sample (1,000+) ✅
Long Follow-up (1yr+) ❌
Independent Funding ❌
Peer-Reviewed ✅
Results Reproduced ✅

mRESVIA (Moderna) — ConquerRSV Phase 3

Wilson et al., Lancet 2023

7/9
Sample size N = 35,541
Follow-up ~4 months
Reported efficacy 83.7% against RSV lower respiratory tract disease
Funding Moderna (manufacturer)
7/9 criteria met (78%)
Criterion Met
Control Group ✅
Randomized ✅
Double-Blind ✅
Placebo-Controlled ✅
Large Sample (1,000+) ✅
Long Follow-up (1yr+) ❌
Independent Funding ❌
Peer-Reviewed ✅
Results Reproduced ✅

Side-by-Side Comparison

Criterion Arexvy (GSK)Abrysvo (Pfizer)mRESVIA (Moderna)
Control Group✅✅✅
Randomized✅✅✅
Double-Blind✅✅✅
Placebo-Controlled✅✅✅
Large Sample (1,000+)✅✅✅
Long Follow-up (1yr+)❌❌❌
Independent Funding❌❌❌
Peer-Reviewed✅✅✅
Results Reproduced✅✅✅
Total score 7/97/97/9
Methodology note: A lower score does not mean a vaccine is unsafe or ineffective. It means the published evidence has methodological gaps — shorter follow-up, manufacturer funding, or non-standard controls. We evaluate methodology only. Consult your healthcare provider about vaccination decisions.
← Back to all vaccine scorecards